Press release
Breast Cancer Biomarker Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Sermonix Pharmaceuticals, Novartis, Pfizer
The latest healthcare forecast report provides an in-depth analysis of Breast Cancer Biomarker, offering comprehensive insights into the Breast Cancer Biomarker revenue trends, prevalence, and treatment landscape. The report delves into key Breast Cancer Biomarker statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Breast Cancer Biomarker therapies. Additionally, we cover the landscape of Breast Cancer Biomarker clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Breast Cancer Biomarker treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Breast Cancer Biomarker space.
To Know in detail about the Breast Cancer Biomarker market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Breast Cancer Biomarker Market Forecast
https://www.delveinsight.com/sample-request/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Breast Cancer Biomarker Market Report:
• The Breast Cancer Biomarker market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In November 2024, Puma Biotechnology has launched the Phase II ALISCA-Breast1 trial to assess oral alisertib, a selective aurora kinase A inhibitor, for treating breast cancer. The trial will evaluate alisertib in combination with endocrine therapy for patients with hormone receptor-positive (HR+), HER2-negative recurrent or metastatic breast cancer who previously received treatment with CDK4/6 inhibitors and endocrine therapy.
• The overall market size for ER+/HER2- breast cancer in the 7MM was around USD 7,400 million in 2022 and is expected to grow throughout the forecast period (2023-2032).
• The existing treatment market for ER+/HER2- Breast Cancer in the adjuvant and neoadjuvant settings includes aromatase inhibitors, tamoxifen, chemotherapy, the CDK4/6 inhibitor Verzenio, among others. In 2019, the total treatment market for ER+/HER2- Breast Cancer in the US was estimated at around USD 6,300 million.
• In 2022, the market size for ER+/HER2- breast cancer in the first-line setting in the United States was approximately USD 3,800 million and is expected to grow over the forecast period (2023-2032).
• ORSERDU is the first endocrine breakthrough in 20 years, targeting ESR1 mutations in ER+, HER2-, advanced, or metastatic breast cancer patients whose disease has progressed after at least one line of endocrine therapy.
• Key Breast Cancer Biomarker Companies: AstraZeneca, Sermonix Pharmaceuticals, Novartis, Pfizer, and others
• Key Breast Cancer Biomarker Therapies: Camizestrant (AZD9833), Lasofoxifene, KISQALI (ribociclib), LYNPARZA (olaparib), FASLODEX (fulvestrant), IBRANCE (palbociclib), and others
• The Breast Cancer Biomarker market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Breast Cancer Biomarker pipeline products will significantly revolutionize the Breast Cancer Biomarker market dynamics.
• In 2023, approximately 297,790 new cases of breast cancer in women are expected to be diagnosed in the United States.
• Breast cancer ranks as the most common cancer among women in the United States, aside from skin cancers. It accounts for around 30% (or 1 in 3) of all newly diagnosed cancers in women each year. About 0.5-1% of breast cancer cases are found in men.
• The HR+/HER2- subtype of breast cancer is the most prevalent, with an age-adjusted incidence rate of 87.2 new cases per 100,000 women in the United States.
• In the United States, breast cancer cases are predominantly seen in postmenopausal women, accounting for approximately 80-20% of the total cases, whereas premenopausal women represent a much smaller share of the patient population.
• Among the different subtypes of the disease (localized and regional), ER+/HER2- had the largest patient population, with around 140,000 cases reported in 2022. This was followed by approximately 24,000 cases of Triple-negative and about 20,000 cases of ER+/HER2+. Meanwhile, HR-/HER2+ accounted for the fewest cases.
Breast Cancer Biomarker Overview
A breast cancer biomarker is a biological molecule found in blood, tissue, or other body fluids that indicates the presence or behavior of breast cancer. Biomarkers can help diagnose the disease, predict its progression, and guide treatment decisions. Common breast cancer biomarkers include hormone receptors (like estrogen and progesterone receptors), HER2 protein, and BRCA gene mutations. These markers are crucial for selecting targeted therapies and personalizing patient care.
Get a Free sample for the Breast Cancer Biomarker Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Breast Cancer Biomarker Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Breast Cancer Biomarker Epidemiology Segmentation:
The Breast Cancer Biomarker market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Breast Cancer Biomarker
• Prevalent Cases of Breast Cancer Biomarker by severity
• Gender-specific Prevalence of Breast Cancer Biomarker
• Diagnosed Cases of Episodic and Chronic Breast Cancer Biomarker
Download the report to understand which factors are driving Breast Cancer Biomarker epidemiology trends @ Breast Cancer Biomarker Epidemiology Forecast
https://www.delveinsight.com/sample-request/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Breast Cancer Biomarker Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Breast Cancer Biomarker market or expected to get launched during the study period. The analysis covers Breast Cancer Biomarker market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Breast Cancer Biomarker Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Breast Cancer Biomarker Therapies and Key Companies
• Camizestrant (AZD9833): AstraZeneca
• Lasofoxifene: Sermonix Pharmaceuticals
• KISQALI (ribociclib): Novartis
• LYNPARZA (olaparib): AstraZeneca
• FASLODEX (fulvestrant): AstraZeneca
• IBRANCE (palbociclib): Pfizer
Discover more about therapies set to grab major Breast Cancer Biomarker market share @ Breast Cancer Biomarker Treatment Landscape
https://www.delveinsight.com/sample-request/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Breast Cancer Biomarker Market Drivers
• Advancements in Technology
• Rising Incidence of Breast Cancer
• Personalized Medicine
• Rising Awareness
• Government Support
• Regulatory Approvals
Breast Cancer Biomarker Market Barriers
• High Costs
• Complexity in Biomarker Validation
• Lack of Standardization
• Regulatory Hurdles
• Limited Awareness in Low-Income Regions
• Data Privacy and Ethical Concerns
Scope of the Breast Cancer Biomarker Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Breast Cancer Biomarker Companies: AstraZeneca, Sermonix Pharmaceuticals, Novartis, Pfizer, and others
• Key Breast Cancer Biomarker Therapies: Camizestrant (AZD9833), Lasofoxifene, KISQALI (ribociclib), LYNPARZA (olaparib), FASLODEX (fulvestrant), IBRANCE (palbociclib), and others
• Breast Cancer Biomarker Therapeutic Assessment: Breast Cancer Biomarker current marketed and Breast Cancer Biomarker emerging therapies
• Breast Cancer Biomarker Market Dynamics: Breast Cancer Biomarker market drivers and Breast Cancer Biomarker market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Breast Cancer Biomarker Unmet Needs, KOL's views, Analyst's views, Breast Cancer Biomarker Market Access and Reimbursement
To know more about Breast Cancer Biomarker companies working in the treatment market, visit @ Breast Cancer Biomarker Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Breast Cancer Biomarker Market Report Introduction
2. Executive Summary for Breast Cancer Biomarker
3. SWOT analysis of Breast Cancer Biomarker
4. Breast Cancer Biomarker Patient Share (%) Overview at a Glance
5. Breast Cancer Biomarker Market Overview at a Glance
6. Breast Cancer Biomarker Disease Background and Overview
7. Breast Cancer Biomarker Epidemiology and Patient Population
8. Country-Specific Patient Population of Breast Cancer Biomarker
9. Breast Cancer Biomarker Current Treatment and Medical Practices
10. Breast Cancer Biomarker Unmet Needs
11. Breast Cancer Biomarker Emerging Therapies
12. Breast Cancer Biomarker Market Outlook
13. Country-Wise Breast Cancer Biomarker Market Analysis (2019-2032)
14. Breast Cancer Biomarker Market Access and Reimbursement of Therapies
15. Breast Cancer Biomarker Market Drivers
16. Breast Cancer Biomarker Market Barriers
17. Breast Cancer Biomarker Appendix
18. Breast Cancer Biomarker Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Latest Reports by DelveInsight
• Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
• Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market
• Neuroendoscopy Market: https://www.delveinsight.com/report-store/neuroendoscopy-market
• Nosocomial Infections Market: https://www.delveinsight.com/report-store/nosocomial-infections-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Breast Cancer Biomarker Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Sermonix Pharmaceuticals, Novartis, Pfizer here
News-ID: 3993409 • Views: …
More Releases from DelveInsight Business Research
Global Functional Electrical Stimulation Devices Market to grow at a CAGR of 8.2 …
According to DelveInsight's analysis, the growing demand for Functional Electrical Stimulation (FES) devices is mainly driven by the rising incidence of musculoskeletal disorders worldwide. Additionally, the increasing focus on pain management therapies and technological advancements in product development are expected to further boost the FES market in the coming years.
DelveInsight's "Functional Electrical Stimulation Devices Market Insights, Competitive Landscape and Market Forecast-2030" report provides the current and forecast market outlook, forthcoming…
Global Intracardiac Echocardiography Devices Market to grow at a CAGR of 5.33% b …
According to DelveInsight's analysis, the demand for intracardiac echocardiography devices is mainly driven by the growing prevalence of arrhythmias, atrial septal defects, and other cardiovascular conditions. Additionally, the increasing number of elderly patients, a rising preference for minimally invasive procedures, the surge in lifestyle-related diseases, and advancements in cardiac-related technologies are all contributing to the overall growth of the intracardiac echocardiography devices market during the forecast period from 2024 to…
Global Anti-Snoring Devices Market to reach USD 2.58 million at a CAGR of 7.02% …
According to DelveInsight's analysis, the Anti-Snoring Device Market is set for significant growth due to the rising prevalence of sleep disorders and associated risk factors like depression, COPD, and obesity. Additionally, an increase in sleep awareness campaigns, as well as the introduction of advanced sleep devices, will drive market expansion from 2024 to 2030.
DelveInsight's "Anti-Snoring Devices Market Insights, Competitive Landscape and Market Forecast-2030" report provides the current and forecast market…
Intratumoral Cancer Therapies Market Predicted to See Upsurge Through 2034, High …
DelveInsight's "Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Intratumoral Cancer Therapies, historical and forecasted epidemiology as well as the Intratumoral Cancer Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Intratumoral Cancer Therapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Intratumoral Cancer Therapies…
More Releases for Breast
Breast Ultrasound Market Research Report and Forecast to 2028 - Conventional Bre …
A breast ultrasound is an imaging method chiefly utilized to screen for tumours and other breast abnormalities. The ultrasound use high-frequency sound waves for the production of detailed images of the inside of the breasts.
The global Breast Ultrasound Market is expected to grow at a significant CAGR of 14.6% by 2028.
The updated report on the Breast Ultrasound market gives a precise analysis of the value chain assessment for the review…
Breast Imaging Market by Breast Ultrasound, Breast MRI, Automated Whole-Breast U …
Growth of breast imaging market driven by factors like rising incidence of breast cancer globally, growing government investments and funding for breast cancer treatment and related research, increasing awareness about early detection of breast cancer, rising geriatric population, technological advancements in breast imaging modalities, and launch of advanced breast imaging systems capable of detecting cancer in women with dense breast tissues.
Download Free PDF Brochure on Brest Imaging Market Report Now…
Breast Implants Market Report 2018: Segmentation by Product (Silicone Breast Imp …
Global Breast Implants market research report provides company profile for Allergan, Mentor Worldwide LLC, Hans biomed, Establishment Labs, Polytech Health & Aesthetics, Sientra, Inc., GC Aesthetics, Cereplas and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to…
Automated Breast Ultrasound Systems – The Future of Breast Screening
Breast cancer is the most commonly diagnosed type of cancer and the second leading cause of death among women, as evident from stats revealed by the National Breast Cancer Foundation. Growing awareness of breast cancer has increased number of women undergoing breast screening and in turn would propel demand for automated breast ultrasound systems (ABUS) in hospitals and diagnostic centers. ABUS enables physicians to screen women, especially with denser breasts…
Soaring Instances of Breast Cancer to Propel Breast Imaging Market
"The Report Breast Imaging Market (Mammography, Breast MRI, Breast Ultrasound, Tomosynthesis, Nuclear Imaging and Others [Breast Thermography & Bioelectric Imaging]) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
An intelligence report on the global breast imaging market has been added to the burgeoning portfolio of MarketResearchReports.biz. Titled, “Breast Imaging…
What Is A Combined Breast Augmentation With Breast Lift?
Combined Breast Augmentation And Lift: How Is It Performed?
Surrounding the areola one incisions is made to remove the excess skin and another vertically incisions is made to the base of breasts starting from low part of the areola. Sometimes the scar is referred to as the “Lollipop scar”. Implants are placed through the incisions made and positioned carefully by the surgeon under the pectoral chest muscle, where the implants can…
